The Indian pharma industry is showing signs of healthy growth and is likely to be in the top 10 global markets by value by 2020. Over the past year, there have been interventions at the regulatory level such as compulsory licensing, FDI policy, marketing code and regulatory approvals, which requires better planning for future growth.
Majority of India pharma companies have reported disappointing results in 2018 compared to last year. Analysts believe the sharp drop in margins are due to regulatory and pricing challenges in global market in addition to the changes created by GST implementation in India. The Indian pharma industry has been facing several regulatory challenges which require careful consideration by the companies as they think through suitable strategies in their pursuit of growth.
Join us at the 8th Annual Global Pharma Regulatory Summit scheduled to be held in Mumbai on 29 to 31 May 2019 as this unique platform is designed to host key leaders and experts of regulatory affairs, compliances, quality assurance and policy makers to discuss the current trends and challenges in global regulatory landscape.
The Conference program will include dialogues and discussions on Brexit, GDPR, third party operation, post-approval changes and life-cycle management, challenges of regulatory application submissions. Attendees will also learn about current topics, such as changing face of pharma legislation, impact of technologies on regulatory system, regulatory landscape of South America, and many others.
Dr. T.V. Narayana
India Pharmaceutical Association
Chairman of Regulatory Affairs Committee
Indian Drug Manufacturer’s Association
Dr Ian Hudson
Medicines and Healthcare Products Regulatory Agency (MHRA)
Head Global Data Privacy
Executive Vice President, Regulatory Affairs (Indian Sub Continent)
President - Global Quality & Regulatory
Senior Vice President & Head Global Regulatory Affairs
SVP - Quality and RA
Piramal Pharma Solutions
Director- Regulatory and Medical Affairs, South Asia
Senior Vice President Regulatory
Intas Pharmaceuticals Ltd
Director – RA
Aurobindo Pharma Ltd